Honey bee envenoming in Santa Catarina, Brazil, 2007 through 2017: an observational, retrospective cohort study

Oliveira, Suzana Kniphoff de; Trevisol, Daisson José; Parma, Gabriel Cremona; Júnior, Rui Seabra Ferreira; Barbosa, Alexandre Naime; Barraviera, Benedito; Schuelter-Trevisol, Fabiana

doi:10.1590/0037-8682-0418-2018

Cited by 8 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They described that Afribumab 1 and 2 alone reduced the cytotoxic activities of honeybee venom components, and the mixture of both antibodies improved this inhibition [30,37]. Most of these observations are in agreement with our present data, showing the necessity of developing a specific treatment, a safe agent that can counteract and stop the deleterious effects caused by a massive, Africanized honeybee attack, which is a health problem in Brazil and other countries in the Americas [6,8,[13][14][15][16][17].…”

Section: Discussionsupporting

confidence: 92%

“…When threatened, these insects become aggressive and can attack massively, causing serious and occasionally fatal cases [12][13][14]. On a temporal scale, over the years the number of cases reported in Brazil has increased exponentially, as demonstrated by epidemiological studies [15,16] and data from the Brazilian National Disease Notification System (SINAN) [17]. Between the years 2000 and 2017, the number of notifications raised by 11-fold (from 1440 to 17,078 cases, respectively) [17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Novel Apilic Antivenom to Treat Massive, Africanized Honeybee Attacks: A Preclinical Study from the Lethality to Some Biochemical and Pharmacological Activities Neutralization

Teixeira-Cruz

Strauch

Monteiro-Machado

et al. 2021

Toxins

Self Cite

View full text Add to dashboard Cite

Massive, Africanized honeybee attacks have increased in Brazil over the years. Humans and animals present local and systemic effects after envenomation, and there is no specific treatment for this potentially lethal event. This study evaluated the ability of a new Apilic antivenom, which is composed of F(ab’)2 fraction of specific immunoglobulins in heterologous and hyperimmune equine serum, to neutralize A. mellifera venom and melittin, in vitro and in vivo, in mice. Animal experiments were performed in according with local ethics committee license (UFRJ protocol no. DFBCICB072-04/16). Venom dose-dependent lethality was diminished with 0.25–0.5 μL of intravenous Apilic antivenom/μg honeybee venom. In vivo injection of 0.1–1 μg/g bee venom induced myotoxicity, hemoconcentration, paw edema, and increase of vascular permeability which were antagonized by Apilic antivenom. Cytotoxicity, assessed in renal LLC-PK1 cells and challenged with 10 μg/mL honeybee venom or melittin, was neutralized by preincubation with Apilic antivenom, as well the hemolytic activity. Apilic antivenom inhibited phospholipase and hyaluronidase enzymatic activities. In flow cytometry experiments, Apilic antivenom neutralized reduction of cell viability due to necrosis by honeybee venom or melittin. These results showed that this antivenom is effective inhibitor of honeybee venom actions. Thus, this next generation of Apilic antivenom emerges as a new promising immunobiological product for the treatment of massive, Africanized honeybee attacks.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

A Novel Apilic Antivenom to Treat Massive, Africanized Honeybee Attacks: A Preclinical Study from the Lethality to Some Biochemical and Pharmacological Activities Neutralization

Teixeira-Cruz

Strauch

Monteiro-Machado

et al. 2021

Toxins

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similarly, can also be the case for Apis mellifera massive attacks when thousands of bees will inject up to half a gram of venom. The expansion of Africanized honeybees (AHB) throughout the Americas (2, 4, 5, 13) and consequently the severity of their accidents also forced health authorities to classify such accidents as an object of health surveillance as in Brazil ( Figure 1 ) (14).…”

Section: Introductionmentioning

confidence: 99%

A phase I/II trial to treat massive Africanized honeybee (Apis mellifera) stings using the new apilic antivenom

Barbosa

Ferreira

Carvalho

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Safety, optimal minimum dose, and, preliminary effectiveness of a new generation Africanized honeybees (Apis mellifera) antivenom (AAV) were evaluated. A phase I/II, multicenter, non- randomized, single-arm clinical trial involving 20 participants showing multiple stings were studied. Participants have received either 2 to 10 vials of AAV based on the stings number together with a predefined adjuvant, symptomatic, and complementary treatment schedule. The primary safety endpoint was the presence of early adverse reactions within the first 24 hours after treatment. Preliminary efficacy through clinical evolution, including laboratory tests, was assessed at baseline and over the following four weeks. ELISA assays and mass spectrometry estimated the venom pharmacokinetics before, during, and after treatment. Twenty adult participants, 13 (65%) males, and 7 (35%) females, with a median age of 44 years and a mean body surface of 1.92 m2 (median = 1.93 m2) were recruited. The median number of stings was 52.5 ranging from 7 to more than 2,000. Envenoming severity was classified as 80% mild, 15% moderate, and 5% severe. According to the protocol, 16 (80%) participants received two AAV vials, 3 (15%) six vials, and one (5%) 10 vials. There was no discontinuation of the treatment due to acute adverse events and there were no late adverse reactions. Two patients showed mild adverse events with only transient itchy skin and erythroderma. All participants completed the infusion within two hours and there was no loss of follow-up after discharge. ELISA assays showed venom concentrations varying between 0.25 ng/mL and 1.479 ng/mL prior to treatment. Venom levels decreased in all cases during the hospitalization period. Surprisingly, in nine cases (45%), despite clinical recovery and without symptoms, the venom levels increased again during outpatient care 10 days after discharge. Mass spectrometry showed melittin in eight participants 30 days after the treatment. Considering the promising safety results of the investigational product for the treatment of massive Africanized honeybee attacks, added to efficacy in clinical improvement and immediate decrease in blood venom level, the AAV has shown to be safe for human use.Trial registrationUniversal Trial Number (UTN): U1111-1160-7011, Register Number: RBR-3fthf8 (http://www.ensaiosclinicos.gov.br/rg/RBR-3fthf8/).

show abstract

Phospholipase A2 induces acute kidney injury by complement mediated mitochondrial apoptosis via TNF-α/NF-κB signaling pathway

Tang

Wei

Guan

et al. 2023

Food and Chemical Toxicology

View full text Add to dashboard Cite

Honey bee envenoming in Santa Catarina, Brazil, 2007 through 2017: an observational, retrospective cohort study

Cited by 8 publications

References 9 publications

A Novel Apilic Antivenom to Treat Massive, Africanized Honeybee Attacks: A Preclinical Study from the Lethality to Some Biochemical and Pharmacological Activities Neutralization

A Novel Apilic Antivenom to Treat Massive, Africanized Honeybee Attacks: A Preclinical Study from the Lethality to Some Biochemical and Pharmacological Activities Neutralization

A phase I/II trial to treat massive Africanized honeybee (Apis mellifera) stings using the new apilic antivenom

Phospholipase A2 induces acute kidney injury by complement mediated mitochondrial apoptosis via TNF-α/NF-κB signaling pathway

Contact Info

Product

Resources

About